Eukles Asset Management’s Pfizer PFE Stock Holding History

Eukles Asset Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.26K	Hold	45	–	–	﹤0.01%	208
2025 Q4	$1.12K	Hold	45	–	–	﹤0.01%	210
2025 Q3	$1.15K	Hold	45	–	–	﹤0.01%	218
2025 Q2	$1.09K	Hold	45	–	–	﹤0.01%	218
2025 Q1	$1.14K	Hold	45	–	–	﹤0.01%	201
2024 Q4	$1.19K	Hold	45	–	–	﹤0.01%	205
2024 Q3	$1.3K	Hold	45	–	–	﹤0.01%	215
2024 Q2	$1.26K	Hold	45	–	–	﹤0.01%	214
2024 Q1	$1.25K	Hold	45	–	–	﹤0.01%	214
2023 Q4	$1.3K	Hold	45	–	–	﹤0.01%	222
2023 Q3	$1.49K	Hold	45	–	–	﹤0.01%	218
2023 Q2	$1.65K	Hold	45	–	–	﹤0.01%	212
2023 Q1	$1.84K	Hold	45	–	–	﹤0.01%	196
2022 Q4	$2K	Hold	45	–	–	﹤0.01%	194
2022 Q3	$2K	Buy	+45	New	+$2.19K	﹤0.01%	192

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Eukles Asset Management's PFE Position: Q1 2026 in Review

Eukles Asset Management held its Pfizer (PFE) position steady in Q1 2026 at 45 shares worth $1.26K. The position accounts for ﹤0.01% of the portfolio, ranked #208.

Eukles Asset Management first reported a position in PFE in Q3 2022 and has held it in 15 quarters since. The position peaked at $2K in Q4 2022. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

Eukles Asset Management held 45 shares of Pfizer worth $1.26K as of Q1 2026.
Eukles Asset Management left its Pfizer share count unchanged in Q1 2026.
Pfizer made up ﹤0.01% of Eukles Asset Management's portfolio in Q1 2026, its #208 holding.
Eukles Asset Management first reported a position in Pfizer in Q3 2022 and has held it in 15 quarters since.
Eukles Asset Management's Pfizer position peaked at $2K in Q4 2022.
2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Eukles Asset Management's 13F filing for Q1 2026, filed 5 May 2026.